drugset / Trial / NCT02323529

Efficacy and Safety of Once Daily Dosing Compared to Twice Daily Dosing of Nitisinone in HT-1

NCT02323529

Phase 3 Completed 18 enrolled Swedish Orphan Biovitrum
CrossoverOpen-labelTreatment

Summary

The purpose of this study is to look at the steady-state serum concentrations of nitisinone when switching from twice daily and once daily dosing.

Timeline

Start
2014-12
Primary completion
2015-09
Completion
2015-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Nitisinone Small molecule 1 mg/kg
Subject Nitisinone Small molecule 2 mg/kg

Indications